TP53 R249S

CI-VAR-00003788Explore in graph →ClinVar 406598 CIViC 1696 rs28934571

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
TP53 R249S	MDM2 Inhibitor AMGMDS3	Predictive	D	Supports Resistance	4	accepted	EID4888 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Unmapped disease5unmapped disease
TP53 R249S	(functional)	Functional	D	Supports Loss Of Function	3	submitted	EID7110 A reporter assay in FASAY yeast strain using the ADE2 gene under control of the p-21 or RGC p53 response elements was performed to assay p53 hotspot mutation R249S transcriptional activity, with colon… (full text at CIViC)

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
406598	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Li-Fraumeni syndrome; Li-Fraumeni syndrome 1; Glioma susceptibility 1	germline	3	May 04, 2026	clinvar